Back to search

Aristotle University Of Thessaloniki (AUTH)

Φαρμακοχημική μελέτη υβριδίων με φυσικά αμινοξέα στη φλεγμονή

Abstract

dc:description

Cinnamic acids comprise a diverse group of bioactive agents. They exhibit many biological activities e.g. anticancer, neuroprotective, antioxidant, anti-inflammatory etc. Several cinnamic acid derivatives are used as therapeutic agents, e.g. Tranilast – an anti-allergic drug, and Ozagrel – an anticoagulant. Cinnamic acids are the precursors of coumarins, another group of highly bioactive agents, exhibiting antioxidant, antiviral and anticancer activities, among others.The term “multifactorial diseases” is used to describe those cases where several biological targets are implicated in the development of a pathological condition. Inflammation and cancer are considered multifactorial diseases since they entail the activity of several biological targets among them cyclooxygenase and lipoxygenase. Hybrid molecules, which include the pharmacophore groups of several bioactive molecules in a single molecular entity, could be used as therapeutic agents for multifactorial diseases, due to the fact of their pleiotropic activities profile of better pharmacokinetic behavior and lower toxicity.Relying on the previous expertise of our group on developing potent lipoxygenase and cyclooxygenase inhibitors incorporating the cinnamic acid and coumarin moieties, in the present thesis, novel substituted cinnamic acid and coumarin hybrids with neurotransmitter amino acids (glycine, GABA and L-glutamic acid) were designed as possible anti-inflammatory and neuroprotective agents following previous 2D-QSAR models and modelling studies. Their drug-likeness was in silico predicted. A library of 100 hybrid molecules was performed from which the most theoretically potent were selected to be synthesized.All the starting materials were prepared using literature-described methodologies. The compounds were characterised by their physicochemical and spectral properties. Several cinnamic acids were purchased for commercial sources and were used without purification. The final amide products were synthesised based on known and modified methodologies. Their structure was confirmed using spectroscopic techniques (1H-NMR, 13C-NMR, IR, HRMS). None of the final synthesized molecules was found to violate Lipinki’s rule of five (using Molinspiration tool). All are considered as active following per os administration. Their BBB permeability study (SwissADME, PreADMET and Molsoft tools) showed that only a few molecules (2, 3, 4, 8, 9, 10, 11, 12, 13, 18, 20, 24, 26, 27, 28, 32, 33, 34, 37, 42 and 44) would penetrate the BBB, while their hybrid structure could offer alternative penetration modes (e.g. active transport). None acts as Pgp substrate. All compounds were found to be highly absorbed by the GI tract (PreADMET tool) and are highly bound to the plasma proteins. The study of their metabolic profile (GLORYx tools) revealed that coumarin hybrids are mainly metabolised via Phase I (hydrolysis of the ester moiety and hydroxylation at position 3 of the coumarin nucleus) while cinnamate hybrids via Phase II (conjugation with glutathione). All compounds showed in silico a high probability for hepatotoxic effect (LiverTox Workspace tool).The final products were studied for a) their antioxidant activity, as AAPH-induced linoleic acid peroxidation inhibitors, b) their lipoxygenase inhibitory activity, c) their cyclooxygenase-2 inhibitory activity, d) their anti-inflammatory activity as albumin denaturation inhibitors, and e) their ATXN1 accumulation inhibition.The results showed that compounds 2 and 18 were the most potent COX-2 inhibitors, with IC50 values of 5 and 6 μΜ respectively. Compounds exhibit a pleiotropic profile since they show both high anti-LOX activity and high antioxidant efficacy (compounds 19, 50, 60, 61, 66 and 68) or high anti-COX-2 activity and high antioxidant efficacy (compounds 8, 11, 17, 24, 43, and 69) or high anti-LOX and anti-COX-2 activity compounds (6 and 59) or even against all the evaluated protocols (compounds 60 and 69). Compound 68 exhibited the highest anti-LOX activity with an IC50 value of 8.5 μΜ and showed a competitive mode of action. Compound 68 also exhibited a good ATXN1 accumulation inhibitory activity. Compound 68 could act as a lead compound for the development of novel LOX inhibitors while compounds 6 and 59 could act as lead compounds for the design of potent dual LOX/COX-2 inhibitors.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Fotopoulos, Ioannis
  • Φωτόπουλος, Ιωάννης

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/51198

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Fotopoulos, Ioannis; Φωτόπουλος, Ιωάννης. Φαρμακοχημική μελέτη υβριδίων με φυσικά αμινοξέα στη φλεγμονή. Aristotle University Of Thessaloniki (AUTH), 2022. http://hdl.handle.net/10442/hedi/51198